Genovo

Genova Biotech is a global biopharmaceutical company specializing in the innovation, development, and large-scale production of novel therapeutic proteins. The company leverages two proprietary technology platforms: one for engineering high-potency proteins with enhanced functional activity and another for creating long-acting proteins with extended blood half-life using a mutated human Fc fragment. Its flagship product, Novaferon, is a first-in-class recombinant protein approved in China for the treatment of chronic Hepatitis B and is currently being evaluated for anti-tumor and broad-spectrum antiviral applications. Genova's pipeline includes long-acting versions of erythropoietin (Nova-EPO) and GM-CSF, alongside late-stage biosimilar programs for insulin analogs and human growth hormone.